Valuation: Compass Therapeutics, Inc.

Market Cap 367M 322M 300M 276M 518M 35.1B 527M 3.56B 1.39B 17.41B 1.38B 1.35B 60.14B P/E 2026 *
-4.68x
P/E 2027 * -4.39x
Enterprise Value 217M 191M 178M 163M 306M 20.77B 312M 2.11B 825M 10.3B 816M 798M 35.58B EV / Sales 2026 *
-106x
EV / Sales 2027 * 9.31x
Free-Float
87.55%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 65 2024-05-27
Director of Finance/CFO 54 2024-12-08
Chief Tech/Sci/R&D Officer 50 2025-12-31
Director TitleAgeSince
Director/Board Member 65 2013-12-31
Director/Board Member 64 2014-12-31
Chairman 61 2014-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-10.80%+32.67% - - 375M
-2.25%+1.55%+50.84%+70.04% 56.19B
-1.32%-2.71%+34.27%+77.57% 54.83B
+1.49%+0.13%-18.03%-13.94% 23.04B
-0.57%-4.13%+2.34%+387.73% 22.7B
+1.97%+1.29%+17.08%-10.79% 20.23B
0.00%+3.00%+27.41%-29.52% 17.83B
-5.84%-7.39%+21.46%+533.75% 15.65B
-6.69%-5.11%+169.13%+304.89% 15.24B
+1.25%+0.69%+27.30%+184.69% 14.03B
Average -2.28%-0.17%+36.87%+167.16% 26.64B
Weighted average by Cap. -1.32%-0.21%+35.47%+131.46%

Financials

2026 *2027 *
Net sales -2.06M -1.81M -1.68M -1.55M -2.9M -197M -2.95M -19.94M -7.81M -97.47M -7.72M -7.56M -337M 25.27M 22.18M 20.65M 18.99M 35.6M 2.41B 36.22M 245M 95.89M 1.2B 94.86M 92.82M 4.14B
Net income -82.44M -72.35M -67.37M -61.96M -116M -7.88B -118M -799M -313M -3.91B -309M -303M -13.49B -89.57M -78.6M -73.2M -67.32M -126M -8.56B -128M -868M -340M -4.24B -336M -329M -14.66B
Net Debt -150M -132M -123M -113M -211M -14.33B -215M -1.45B -569M -7.11B -563M -551M -24.55B -132M -116M -108M -99.22M -186M -12.61B -189M -1.28B -501M -6.25B -496M -485M -21.61B
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
2.040USD
Average target price
8.500USD
Spread / Average Target
+316.67%

Quarterly revenue - Rate of surprise